This document is a USPTO patent application (US20260083747A1) for novel compositions designed to support mitochondrial health. The application describes specific formulations containing methylthioninium salts combined with other mitochondria-enhancing compounds such as urolithin A, pyrroloquinoline quinone, or tesofensine, detailing precise weight ratios for these combinations. The filing date for this application was October 30, 2024.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in the pharmaceutical and biotechnology sectors. Companies involved in drug development, particularly those focusing on metabolic health or aging, should be aware of this filing for competitive intelligence and potential intellectual property considerations. No compliance actions or deadlines are associated with patent applications themselves.